CN1973852B - 一种含苦参生物碱和黄芪皂苷的药物组合物及用途 - Google Patents
一种含苦参生物碱和黄芪皂苷的药物组合物及用途 Download PDFInfo
- Publication number
- CN1973852B CN1973852B CN2006101551774A CN200610155177A CN1973852B CN 1973852 B CN1973852 B CN 1973852B CN 2006101551774 A CN2006101551774 A CN 2006101551774A CN 200610155177 A CN200610155177 A CN 200610155177A CN 1973852 B CN1973852 B CN 1973852B
- Authority
- CN
- China
- Prior art keywords
- radix astragali
- sophorae flavescentis
- radix
- radix sophorae
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title abstract description 26
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 title description 7
- 229940079593 drug Drugs 0.000 title description 6
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 title description 4
- 229930014456 matrine Natural products 0.000 title description 4
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 title 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 title 1
- 229930182490 saponin Natural products 0.000 claims abstract description 29
- 150000007949 saponins Chemical class 0.000 claims abstract description 29
- 229930013930 alkaloid Natural products 0.000 claims abstract description 27
- 230000000973 chemotherapeutic effect Effects 0.000 claims abstract 3
- 239000009636 Huang Qi Substances 0.000 claims description 37
- 235000017709 saponins Nutrition 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- 229960004397 cyclophosphamide Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 19
- 206010028980 Neoplasm Diseases 0.000 abstract description 15
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract description 6
- 235000006533 astragalus Nutrition 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 241001061264 Astragalus Species 0.000 abstract description 3
- 230000001603 reducing effect Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 241000219784 Sophora Species 0.000 abstract 2
- 210000004233 talus Anatomy 0.000 abstract 2
- 230000007721 medicinal effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- ZSBXGIUJOOQZMP-BHPKHCPMSA-N sophoridine Chemical compound C1CC[C@@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-BHPKHCPMSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229930015582 oxymatrine Natural products 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000011127 radiochemotherapy Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- AAGFPTSOPGCENQ-UHFFFAOYSA-N Sophocarpin I Natural products C1CCC2CN3C(=O)C=CCC3C3C2N1CCC3 AAGFPTSOPGCENQ-UHFFFAOYSA-N 0.000 description 2
- IGXQFUGORDJEST-UHFFFAOYSA-N Sophocarpine Natural products O=C1C=CCC2C3CCCC4CCCC(CN12)C34 IGXQFUGORDJEST-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- AAGFPTSOPGCENQ-JLNYLFASSA-N sophocarpine Chemical compound C1CC[C@H]2CN3C(=O)C=CC[C@@H]3[C@@H]3[C@H]2N1CCC3 AAGFPTSOPGCENQ-JLNYLFASSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种含苦参生物碱和黄芪皂苷的药物组合物,其有效成分是苦参的总生物碱和黄芪的总皂苷,苦参总生物碱与黄芪总皂苷的质量比例为1∶0.1~1∶10。本发明将黄芪的皂苷类成分与苦参的生物碱类成分有机地组合起来,共同发挥“祛邪扶正、减毒增效”的功效。实验证明,该组合物对移植性小鼠肿瘤具有明显的抑制作用,且能大幅度提高常用化疗药物的药效,不但能提高机体免疫功能,抑制恶性肿瘤的生长,而且与化疗药物合用时具有协同增效作用,且能够减轻放化疗毒副作用。不同于以饮片配伍为基础的中药复方,该组合物的化学成分比较明确,超过50%的化学成分可以获得准确的定性和定量,因此易于进行质量控制,能够满足现代制药工业的要求。
Description
技术领域
本发明涉及一种抗肿瘤的药物组合物,该药物组合物含有一定比例的苦参生物碱和黄芪皂苷,主要用于治疗恶性肿瘤,同时对化疗药物具有增效减毒作用。
技术背景
多年的临床实践表明,中西医结合防治恶性肿瘤疗效肯定,中药在减轻患者症状,改善免疫功能和机体状况,提高手术、放疗或化疗的疗效,减轻由此产生的毒副作用,提高患者生存质量等方面效果显著。但是,以往的抗肿瘤中药多数由大复方构成,在实际生产中难以满足药品“安全、有效、质量稳定”的要求;而中药活性单体或者单一的药材提取物又失去了中药多途径、多靶点整合调节的特点,难以取得令人满意的疗效。因此,需要开发疗效确切、化学组成相对简单的活性组分配伍中药,使之能够适应现代医药工业和药物评价体系的要求。
黄芪为豆科植物(Astragalus membranaceus(Fisch.)Bge var.mongholicus(Bge.)Hsiao)或膜荚黄芪(Astragalus membranaceus(Fisch.)Bge.)的根。其主要活性成分包括黄芪皂苷类物质。其皂苷类成分主要为9,19-环羊毛脂烷型的四环三萜类型化合物,包括黄芪皂苷I,II,III,IV,V,VI,VII,异黄芪皂苷I,II,IV及其衍生物等。文献报道黄芪提取物能够提高机体免疫功能,加速淋巴细胞的增殖分化、显著增加骨髓及外周血白细胞;能促进IL-2的生成、增强T细胞和巨噬细胞活性。虽然黄芪经常出现在抗肿瘤的中药复方中,但其皂苷成分在体内外都不显示明显的抑制或杀伤肿瘤细胞作用。
苦参(Sophora flavescens Ait.)为豆科槐属植物,其化学成分主要有喹诺里西定类型生物碱和黄酮类化合物。生物碱类成分能通过抑制肿瘤细胞DNA的合成、抑制相关酶活性、影响肿瘤细胞的正常周期来抑制肿瘤细胞增殖;通过控制相关因子的表达来抑制肿瘤的转移;通过影响与肿瘤相关基因的表达、影响端粒酶的活性等途径,来诱发细胞发生凋亡,诱导肿瘤细胞向正常细胞分化,从而起到抗肿瘤作用。苦参生物碱类成分在体内外都具有显著的抑制肿瘤生长作用,但在高剂量下具有一定的毒副作用。
发明内容
本发明的目的在于提供一种一种含苦参生物碱和黄芪皂苷的药物组合物,其有效成分是苦参的总生物碱和黄芪的总皂苷,苦参总生物碱与黄芪总皂苷的质量比例为1∶0.1~1∶10,优化的比例为1∶1~1∶3。
本发明提供的组合物与药物允许的赋形剂或敷料制备成药物制剂,制剂形式为液体制剂或固体制剂,包括口服液、颗粒剂、片剂、冲剂、胶丸、胶囊、缓释剂、滴丸剂或注射剂。所述药物制剂的给药形式为口服给药或注射给药。
黄芪总皂苷和苦参总生物碱可以采用相关领域技术人员了解的各种方法制备获得,包括化学合成和生物转化方法。
所述的药物组合物,含有苦参碱,氧化苦参碱和槐定碱,其含量范围为20-80%,这些化合物也可以通过化学合成或生物转化的途径获得;含有环羊毛脂烷型的四环三萜类型化合物;含有黄芪皂苷I,II,III,IV,V,VI,VII,异黄芪皂苷I,II,其含量范围为10-70%,这些化合物也可以通过化学合成或生物转化的途径获得。
本发明的另一个目的是提供该组合物在抗肿瘤或者肿瘤放化疗辅助药物中的应用。该组合物也可与其他药物组合,在制备抗肿瘤或者肿瘤放化疗辅助药物中的应用。
本发明将黄芪的皂苷类成分与苦参的生物碱类成分有机地组合起来,共同发挥“祛邪扶正、减毒增效”的功效。在该组合物中,黄芪皂苷虽然没有显著的抑瘤作用,但是具有补益效果,能够激发机体的免疫功能;而苦参总碱主要发挥抑瘤作用。实验证明,该组合物对移植性小鼠肿瘤具有明显的抑制作用,且能大幅度提高常用化疗药物的药效,不但能提高机体免疫功能,抑制恶性肿瘤的生长,而且与化疗药物合用时具有协同增效作用,且能够减轻放化疗毒副作用。不同与以饮片配伍为基础的中药复方,该组合物的化学成分比较明确,超过50%的化学成分可以获得准确的定性和定量,因此易于进行质量控制,能够满足现代制药工业的要求。
具体实施方式
为了更好地理解本发明,结合以下实施例作进一步的说明。
实施例1
取黄芪药材粗粉,以适量50%的乙醇加热回流提取药材,提取液冷却过夜后过滤,滤液浓缩上D101大孔吸附树脂,先用水冲洗,然后用30%~70%的乙醇冲洗,吸脱物浓缩、冷冻干燥即得。采用HPLC-ELSD法对提取物进行检测,分析条件是Agilent Extend-C18,流动相流动相为H2O-CH3CN,水相在30min内从70%线性降低至10%;ELSD参数:漂移管温度105℃,载气流速2.7L/min;分别以黄芪皂苷I、II、IV、异黄芪皂苷II和乙酰黄芪皂苷I为检测成分,采用外标法测定其含量。其中黄芪皂苷I、II、IV的含量分别为33%、17%、15%,异黄芪皂苷II的含量为1%,乙酰黄芪皂苷I的含量为5%。
苦参药材粉碎,用0.1-2%盐酸渗漉提取,提取液用氨水调节pH值至中性,经732型离子交换树脂,1-5%氨水洗脱,回收洗脱溶剂,得到苦参总碱。采用高效液相法(HPLC)对其进行检测,分析条件是Agilent Extend-C18,流动相H2O(0.1%THF和0.1%氨水)-MeOH,检测波长220nm,分别以苦参碱、氧化苦参碱、槐定碱、槐果碱为检测成分,采用外标法定量。按上述HPLC检测,三种成分含量分别为苦参碱4%、氧化苦参碱33%、槐定碱5%、槐果碱1%。
实施例2组合物1(苦参总碱∶黄芪总皂苷=1∶2)抑瘤作用实验
将预先接种H22腹水瘤的小鼠处死,从腹腔中抽取1ml腹水瘤,用生理盐水稀释成1×106个细胞/ml,按0.2ml/只注射于ICR雌性小鼠腋下,24小时后,随机分组,并开始给药。组合物分别以高、中、低剂量给药,连续给药8天后,停药,称小鼠体重,解剖取瘤块分别称重,进行统计分析,结果参见表1。
表1组合物对小鼠H22肝癌的实验治疗作用
与对照组相比,*P<0.01
实施例3组合物2(苦参总碱∶黄芪总皂苷=1∶3)与化疗药物的协同增效实验
将预先接种H22腹水瘤的小鼠处死,从腹腔中抽取1ml腹水瘤,用生理盐水稀释成1×106个细胞/ml,按0.2ml/只注射于ICR雌性小鼠腋下,24小时后,随机分组,并开始给药。化疗药物环磷酰胺的用量为20mg/Kg,肌肉注射,隔日给药;顺铂的用量为1mg/Kg,腹腔注射,每日给药。组合物按照360mg/Kg的剂量灌胃,每日一次,结果参见表2。
表2组合物与化疗药物合用对小鼠H22癌的实验治疗作用
与对照组相比,*P<0.01;**P<0.001
实施例4组合物3(苦参总碱∶黄芪总皂苷=1∶3)对抗环磷酰胺致白细胞计数降低的实验
ICR雄性小鼠,组合物连续每日灌胃7天,剂量分为高、中、低三组。给药2天后,腹腔注射环磷酰胺,100mg/Kg,连续2日。于第7天摘除眼球取血,测白细胞计数,解剖动物,取脏器称重,计算脏器指数,结果参见表3。
表3组合物对抗环磷酰氨致白细胞下降的效果
与模型组比较,*P<0.01,**P<0.01
实施例5片剂制备
取组合物120g(苦参总碱和黄芪皂苷的比例为1∶1)、淀粉180g、糊精10g混和均匀,用10%预胶化淀粉浆粘合,湿法制粒,烘干,加适量硬脂酸镁混和,压成片剂1000片,包衣即得。
实施例6胶囊
将200g组合物(苦参总碱和黄芪皂苷的比例为1∶1)与羟丙基纤维素60g及微粉硅胶30g混和,用适量70%乙醇做湿润剂,湿法制粒,过筛烘干后加入硬脂酸镁,混匀后装胶囊,制成1000粒。
实施例7颗粒剂
取药物组合物120g(苦参总碱和黄芪皂苷的比例为1∶1),加入糊精200g,蔗糖700g,加适量乙醇混匀,过10目筛成粒,60-70℃真空干燥,整粒分装即得。每包重5g。
实施例8滴丸
将200g药物组合物(苦参总碱和黄芪皂苷的比例为1∶1)研磨过筛(100目),加聚乙二醇6000350g和硬脂酸25g混匀,加热至90℃,搅拌至熔化,保持在80-85℃,控速滴入甲基硅油冷却成丸,制得1000粒。
实施例9口服液
取12g药物组合物(苦参总碱和黄芪皂苷的比例为1∶1),加入适量蒸馏水中加热搅拌溶解。另外在温水中加入蔗糖200g,适量防腐剂溶解后合并,加水至1000ml,混匀,冷藏后过滤灌装,灭菌即得1000ml口服液。
实施例10注射剂
取药物组合物12g(苦参总碱和黄芪皂苷的比例为1∶3),加注射用水溶解,加4%吐温80,充分搅匀,调pH至6,8,过滤后加注射用水至1000ml,超滤后精滤,灌装灭菌即得。
实施例11粉针剂
取药物组合物120g(苦参总碱和黄芪皂苷的比例为1∶3),加注射用水至950ml,搅拌溶解,调pH6.8,加注射用水至1000ml,投入0.02%活性炭搅拌10min,过滤,然后超滤、精滤。分装后冷冻干燥,无菌熔封即得。使用前每100g用500ml生理盐水稀释。
Claims (2)
1.一种含苦参总碱和黄芪总皂苷的药物组合物在制备对抗因环磷酰胺致使白细胞计数降低的药物中的应用,该药物组合物的有效成分是苦参总碱和黄芪总皂苷,其质量比为1∶3。
2.一种含苦参总碱和黄芪总皂苷的药物组合物在制备与化疗药物具有协同增效作用的药物中的应用,该药物组合物的有效成分是苦参总碱和黄芪总皂苷,其质量比为1∶3,所述化疗药为环磷酰胺或顺铂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101551774A CN1973852B (zh) | 2006-12-12 | 2006-12-12 | 一种含苦参生物碱和黄芪皂苷的药物组合物及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101551774A CN1973852B (zh) | 2006-12-12 | 2006-12-12 | 一种含苦参生物碱和黄芪皂苷的药物组合物及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1973852A CN1973852A (zh) | 2007-06-06 |
CN1973852B true CN1973852B (zh) | 2010-11-24 |
Family
ID=38124386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101551774A Expired - Fee Related CN1973852B (zh) | 2006-12-12 | 2006-12-12 | 一种含苦参生物碱和黄芪皂苷的药物组合物及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1973852B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103191179A (zh) * | 2013-03-27 | 2013-07-10 | 张宗升 | 中药提取物及其制备方法 |
CN114748490B (zh) * | 2022-04-24 | 2023-12-12 | 南方科技大学 | 一种用于治疗卵巢早衰的药物组合物、应用及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1406585A (zh) * | 2001-09-07 | 2003-04-02 | 中国科学院上海药物研究所 | 一种治疗病毒性心肌炎的药物组合物 |
-
2006
- 2006-12-12 CN CN2006101551774A patent/CN1973852B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1406585A (zh) * | 2001-09-07 | 2003-04-02 | 中国科学院上海药物研究所 | 一种治疗病毒性心肌炎的药物组合物 |
Non-Patent Citations (6)
Title |
---|
周好田等.浅谈抗癌中药有效成分的诱导分化作用.实用中医药杂志19 3.2003,19(3),156至157. |
周好田等.浅谈抗癌中药有效成分的诱导分化作用.实用中医药杂志19 3.2003,19(3),156至157. * |
戴碧涛等.苦参碱联合抗肿瘤药抑制K562细胞增殖的研究.第三军医大学学报27 5.2005,27(5),392至394. |
戴碧涛等.苦参碱联合抗肿瘤药抑制K562细胞增殖的研究.第三军医大学学报27 5.2005,27(5),392至394. * |
潘云苓等.复方苦参加黄芪与化疗治疗晚期癌症的对比观察.肿瘤研究与临床14 2.2002,14(2),123-124. |
潘云苓等.复方苦参加黄芪与化疗治疗晚期癌症的对比观察.肿瘤研究与临床14 2.2002,14(2),123-124. * |
Also Published As
Publication number | Publication date |
---|---|
CN1973852A (zh) | 2007-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102008475A (zh) | 喹诺里西啶生物碱在制备用于治疗肿瘤药物的应用 | |
CN103768534A (zh) | 一种具有抗肿瘤活性的中药组合物 | |
CN101502579B (zh) | 一种用于治疗消化系肿瘤的中药组合物及其制备方法 | |
CN101428033B (zh) | 一种混合构型人参皂苷Rh2及其应用 | |
CN109512857A (zh) | 一种抑制肿瘤生长的甘露糖-中药复合物 | |
CN1919208A (zh) | 一种治疗上皮性肿瘤的药物 | |
CN1973852B (zh) | 一种含苦参生物碱和黄芪皂苷的药物组合物及用途 | |
CN101904974A (zh) | 一种治疗恶性肿瘤疾病的中药组合物及其制备方法 | |
CN101850032A (zh) | 一种具有抗肿瘤作用的中药组合物及其制备方法和应用 | |
CN100589815C (zh) | 一种抗肿瘤的药物组合物 | |
CN1775267A (zh) | 一种开口箭提取物及其制备方法和应用 | |
CN102908340B (zh) | 一种含异甘草黄酮醇的抗肿瘤药物及其应用 | |
CN104069194B (zh) | 一种具有抗癌作用的中药组合物及其制备方法和用途 | |
CN101172143A (zh) | 一种中药复方及其制备方法和用途 | |
CN108159160B (zh) | 一种治疗结直肠癌的联合用药物 | |
CN107840836A (zh) | 淫羊藿素k及其制备方法和在药物上的应用 | |
CN103006789A (zh) | 贞芪缓释制剂的制备方法及产品 | |
CN101007052B (zh) | 一种抗肿瘤药物及其制备方法 | |
CN102858359B (zh) | 一种含有醇溶性且非水溶性甘草提取物的药物组合物,及其药物制剂、制药用途、治疗方法和制备方法 | |
CN101919903B (zh) | 一种冬凌草二萜提取物的制备方法 | |
CN102078409B (zh) | 一种治疗肝癌的中药制剂 | |
CN101549032B (zh) | 具有抗肺癌作用的药物组合物及其在制备抗肺癌药物中的应用 | |
CN104557826A (zh) | 倍半萜内酯化合物,含其的药物组合物及制备方法、应用 | |
CN101125141A (zh) | 一种抗癌药物组合物及其在制备抗癌药物中的应用 | |
CN101590108B (zh) | 一种改变厚朴提取物粘性的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101124 Termination date: 20201212 |
|
CF01 | Termination of patent right due to non-payment of annual fee |